NCT04897919View on ClinicalTrials.gov

Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria

PHASE4CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

October 1, 2017

Study Completion Date

December 1, 2018

Conditions
MalariaEffectiveness
Interventions
DRUG

Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet

Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.

DRUG

Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet

Artemether-Lumefantrine is given as recommended by manufacturer

Trial Locations (1)

Unknown

Bandim Health Centre, Bissau

All Listed Sponsors
lead

Bandim Health Project

OTHER

NCT04897919 - Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria | Biotech Hunter | Biotech Hunter